ADC Therapeutics SA, a clinical-stage oncology-focused biotech focused on the development and commercialization of highly potent antibody drug conjugates (ADCs) for patients suffering from hematological malignancies and solid tumors, has named Jennifer Creel as chief financial officer. Ms. Creel joins ADC Therapeutics from Celgene.   “I’m delighted to welcome Jenn to our senior leadership team,” said Chris Martin, chief executive officer, ADC Therapeutics. “Jenn has a tra...